Intratumoral Administration of L19IL2/L19TNF

NCT02076633 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma, Skin

Interventions

DRUG: L19IL2+L19TNF

Sponsor

Philogen S.p.A.